BERGENBIO ASA (BGBIO.OL) Stock Price, Forecast & Analysis
Europe - Euronext Oslo - OSL:BGBIO - NO0013251173 - Common Stock
BGBIO.OL Key Statistics, Chart & Performance
The current stock price of BGBIO.OL is 1.198 NOK. In the past month the price increased by 0.5%. In the past year, price decreased by -84.53%.
BGBIO.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| ARGX.BR | ARGENX SE | 68.11 | 44.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.50B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 950.81M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 718.23M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About BGBIO.OL
Company Profile
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
Company Info
BERGENBIO ASA
Nygardsgaten 114
Bergen HORDALAND NO
Employees: 14
Phone: 4755961159
BERGENBIO ASA / BGBIO.OL FAQ
What does BGBIO do?
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
Can you provide the latest stock price for BERGENBIO ASA?
The current stock price of BGBIO.OL is 1.198 NOK. The price increased by 5.83% in the last trading session.
What is the dividend status of BERGENBIO ASA?
BGBIO.OL does not pay a dividend.
What is the ChartMill rating of BERGENBIO ASA stock?
BGBIO.OL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of BERGENBIO ASA (BGBIO.OL) based on its PE ratio?
BERGENBIO ASA (BGBIO.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
Can you provide the market cap for BERGENBIO ASA?
BERGENBIO ASA (BGBIO.OL) has a market capitalization of 46.83M NOK. This makes BGBIO.OL a Nano Cap stock.
Can you provide the upcoming earnings date for BERGENBIO ASA?
BERGENBIO ASA (BGBIO.OL) will report earnings on 2025-11-11.
BGBIO.OL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BGBIO.OL. When comparing the yearly performance of all stocks, BGBIO.OL is a bad performer in the overall market: 96.79% of all stocks are doing better.
BGBIO.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGBIO.OL. While BGBIO.OL seems to be doing ok healthwise, there are quite some concerns on its profitability.
BGBIO.OL Financial Highlights
Over the last trailing twelve months BGBIO.OL reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS increased by 70.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.55% | ||
| ROE | -207.87% | ||
| Debt/Equity | 0 |
BGBIO.OL Forecast & Estimates
7 analysts have analysed BGBIO.OL and the average price target is 5.1 NOK. This implies a price increase of 325.71% is expected in the next year compared to the current price of 1.198.
For the next year, analysts expect an EPS growth of 17.6% and a revenue growth -100% for BGBIO.OL